93 related articles for article (PubMed ID: 38023143)
1. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
Jiang A; Wei C; Zhu W; Wu F; Wu B
Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
3. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
4. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Wong S; Kwan ATH; Rhee TG; Teopiz KM; Ho R; Cao B; Mansur RB; Rosenblat JD; Le GH
Expert Opin Drug Saf; 2024 Jun; ():1-5. PubMed ID: 38804896
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jun; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
6. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
J Affect Disord; 2024 May; 360():421-426. PubMed ID: 38795777
[TBL] [Abstract][Full Text] [Related]
7. Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis.
Park T; Hwang M
Expert Rev Cardiovasc Ther; 2024 May; ():1-11. PubMed ID: 38722712
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced tumoral disease: A global pharmacovigilance database analysis.
Zelmat Y; Despas F
Therapie; 2024; 79(2):189-197. PubMed ID: 38042752
[TBL] [Abstract][Full Text] [Related]
9. Blind Spots in Therapy: Unveiling Drug-Induced Angle-Closure Glaucoma Through a National Analysis.
Aftab OM; Khan H; Khouri AS
Ophthalmol Glaucoma; 2024 Apr; ():. PubMed ID: 38679326
[TBL] [Abstract][Full Text] [Related]
10. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system.
Wong S; Le GH; Kwan ATH; Rhee TG; Teopiz KM; Ho RC; Cao B; Rosenblat JD; Mansur R; McIntyre RS
Int Clin Psychopharmacol; 2024 May; ():. PubMed ID: 38727416
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database.
Tan H; Luo L; Li W; Lan W; Chen Y; Huang G; Yang J; Xi X
Andrology; 2024 Jun; ():. PubMed ID: 38831673
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database.
Yang X; Yang B; Li D; Pan W; Tong Q; Wang L; Chen D; Fu C
Clin Drug Investig; 2024 Mar; 44(3):199-207. PubMed ID: 38376794
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
Barbieri MA; Russo G; Sorbara EE; Cicala G; Franchina T; Santarpia M; Speranza D; Spina E; Silvestris N
Front Oncol; 2023; 13():1268672. PubMed ID: 38023143
[TBL] [Abstract][Full Text] [Related]
14. Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database.
Russo G; Barbieri MA; Sorbara EE; Cicala G; Franchina T; Santarpia M; Silvestris N; Spina E
Biomedicines; 2023 Aug; 11(8):. PubMed ID: 37626807
[TBL] [Abstract][Full Text] [Related]
15. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
16. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
Wang Y; Cui C; Ren X; Dong X; Cui W
Front Cardiovasc Med; 2022; 9():988013. PubMed ID: 36312283
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
